University of Michigan , College of Pharmacy, Department of Pharmaceutical Sciences , 428 Church Street, Room 4002 , Ann Arbor , Michigan 48109 , United States.
Drug Product Science and Technology , Bristol-Myers Squibb , 1 Squibb Drive , New Brunswick , New Jersey 08903 , United States.
Mol Pharm. 2018 Nov 5;15(11):5291-5301. doi: 10.1021/acs.molpharmaceut.8b00783. Epub 2018 Oct 26.
The bicarbonate buffer capacity is usually considered in a phase-homogeneous system, at equilibrium, with no CO transfer between the liquid buffer phase and another phase. However, typically, an in vitro bicarbonate buffer-based system is a phase-heterogeneous system, as it entails continuously sparging (bubbling) the dissolution medium with CO in a gas mixture, at constant ratio, to maintain a constant partial pressure of CO and CO molarity at a prescribed value, with CO diffusing freely between the gas and the aqueous phases. The human gastrointestinal tract is also a phase-heterogeneous system, with CO diffusing across the mucosal membrane into the mesenteric arterial blood, which serves as a sink for CO from the intestinal lumen. In this report, a mass transport analysis of the apparent buffer capacity of a phase-heterogeneous bicarbonate-CO system is developed. It is shown that, most significantly, a phase-heterogeneous bicarbonate-CO system can have a much higher buffer capacity than a phase-homogeneous system such that the buffer capacity is dependent on the bicarbonate concentration. It is double that of a phase-homogeneous system at the pH = p K for a monoprotic buffer at the same concentration. This buffer capacity enhancement increases hyperbolically with pH above the p K, thus providing a much stronger buffering to keep the pH in the physiologically neutral range. The buffer capacity will be dependent on the bicarbonate molarity (which in vivo will depend on the bicarbonate secretion rate) and not the pH of the luminal fluid. Further, there is no conjugate acid accumulation as a result of bicarbonate neutralization, since the resulting carbonic acid (HCO) rapidly dehydrates producing CO and HO. The mass transport analysis developed in this report is further supported by in vitro experimental results. This enhanced bicarbonate buffer capacity in a phase-heterogeneous system is of physiological significance as well as significant for the dissolution and absorption of ionizable drugs.
碳酸氢盐缓冲容量通常被认为是在一个相均匀的系统中,在平衡状态下,液体缓冲相和另一个相之间没有 CO 转移。然而,典型的基于碳酸氢盐的体外缓冲系统是一个相不均匀的系统,因为它需要连续地用 CO 对溶解介质进行吹气(鼓泡),以气体混合物的恒定比例,来维持 CO 的分压和 CO 摩尔浓度的恒定值,CO 在气相和水相间自由扩散。人体胃肠道也是一个相不均匀的系统,CO 通过黏膜扩散进入肠系膜动脉血液,肠系膜动脉血液是肠腔中 CO 的汇。在本报告中,开发了一个相不均匀的碳酸氢盐-CO 系统的表观缓冲容量的传质分析。结果表明,最重要的是,相不均匀的碳酸氢盐-CO 系统可以具有比相均匀系统高得多的缓冲容量,使得缓冲容量取决于碳酸氢盐浓度。在相同浓度下,对于单质子缓冲剂,其缓冲容量是相均匀系统的两倍,在 pH = p K 处。这种缓冲容量增强随着 pH 值高于 p K 值呈双曲线增加,从而提供了更强的缓冲作用,使 pH 值保持在生理中性范围内。缓冲容量将取决于碳酸氢盐的摩尔浓度(体内将取决于碳酸氢盐的分泌速率),而不是腔液的 pH 值。此外,由于碳酸氢盐的中和,没有共轭酸的积累,因为生成的碳酸(HCO)迅速脱水生成 CO 和 HO。本报告中开发的传质分析进一步得到了体外实验结果的支持。这种相不均匀系统中碳酸氢盐缓冲容量的增强不仅对可电离药物的溶解和吸收具有重要意义,而且对生理也具有重要意义。